- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00711828
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
A Phase 2 Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib (VELCADE), and Dexamethasone (R-CYBOR-D) in Relapsed Low Grade and Mantle Cell Lymphoma
Visão geral do estudo
Status
Condições
- Linfoma Folicular Grau 1 Recorrente
- Linfoma folicular de grau 2 recorrente
- Linfoma de Células do Manto Recorrente
- Linfoma Esplênico de Zona Marginal
- Waldenstrom Macroglobulinemia
- Linfoma linfocítico pequeno recorrente
- Leucemia Linfocítica Crônica Refratária
- Linfoma de Zona Marginal Extranodal de Tecido Linfóide Associado à Mucosa
- Linfoma Nodal da Zona Marginal
Descrição detalhada
PRIMARY OBJECTIVES:
I. To assess tumor response to R-CyBor-D in patients with relapsed follicular (Gr 1 or 2), mantle cell, marginal zone lymphomas, small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) and lymphoplasmacytic (Waldenstrom's macroglobulinemia) lymphoma.
SECONDARY OBJECTIVES:
I. To evaluate overall survival, progression-free survival, duration of response, and time to treatment failure of patients receiving R-CyBor-D.
II. To describe the adverse event profile (using National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v 3.0) of R-CyBor-D.
III. To evaluate quality of life for patient reported neurotoxicity using the Gynecologic Oncology Group's Functional Assessment of Cancer Therapy (FACT/GOG) neurotoxicity questionnaire, version 4.0.
OUTLINE:
Patients receive rituximab intravenously (IV) on day 1and cyclophosphamide orally (PO), bortezomib IV, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3-6 months for up to 3 years.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85259
- Mayo Clinic in Arizona
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Histological confirmation of relapsed or refractory follicular Grades 1 or 2 lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, or lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia/WM) by biopsy ≤ 6 months prior to registration
- NOTE: MCL diagnosis should be confirmed by cyclin D1 staining or fluorescence in situ hybridization (FISH) (t(11;14))
Measurable disease by computed tomography (CT), positron emission tomography (PET)/CT or magnetic resonance imaging (MRI) scans with lymph nodes ≥2.0 cm in at least one dimension or tumor cells in the blood ≥ 5 x10^9/L
- NOTE: Lymphoplasmacytic lymphoma (WM) patients without lymphadenopathy must have 1.) >10% lymphocytes, lymphoplasmacytic cells or plasma cells on a bone marrow aspirate/biopsy, and 2.) quantitative IgM ≥ 400mg/dL
- Expected survival > 3 months
- ECOG Performance Status (PS) 0, 1 or 2
- Absolute Neutrophil Count ≥ 1200
- Platelet ≥ 75000
- Hemoglobin ≥ 8.0 g/dL
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- Alkaline phosphatase ≤ 3 x ULN
- Aspartate aminotransferase (AST) ≤ 3 x ULN
- Creatinine ≤ 1.5 x ULN
- Female subject is either postmenopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of VELCADE (bortezomib), or agree to completely abstain from heterosexual intercourse
- Male subjects, even if surgically sterilized (i.e., status postvasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse
- Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
- Willingness to return to Mayo Clinic institution for follow-up
- Negative serum pregnancy test done <7 days prior to registration, for women of childbearing potential only
- Willingness to complete questionnaires by themselves or with assistance
Exclusion Criteria:
Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
- Pregnant women -- confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women;
- Nursing women;
- Men or women of childbearing potential who are unwilling to employ adequate contraception
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse event of the prescribed regimen
- Patients known to be human immunodeficiency virus (HIV) positive
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Diagnosed or treated for another malignancy ≤ 3 years prior to registration, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy or low-risk prostate cancer after curative therapy
- NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer
- Patient has received other investigational drugs ≤ 14 days prior to registration
- Patient has hypersensitivity to bortezomib, boron or mannitol
Myocardial infarction ≤ 6 months prior to registration or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
- NOTE: Prior to study entry, any electrocardiogram (ECG) abnormality at Screening has to be documented by the investigator as not medically relevant
- Previous cancer therapy, hormonal therapy and surgery < 4 weeks prior to registration
- Patient has ≥ Grade 2 peripheral neuropathy
Radiation therapy within 3 weeks before randomization
- Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Treatment (R-CYBOR-D)
Patients receive rituximab IV on day 1and cyclophosphamide PO, bortezomib IV, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
|
Dado IV
Outros nomes:
Dado PO
Outros nomes:
Dado PO
Dado IV
Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Proportion of Responses (Complete Response or Partial Response)
Prazo: up to 12 cycles
|
A response is defined to be a Complete Response (CR) or Partial Response (PR) noted as the objective status on any evaluation (i.e., best response).
The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients.
A confidence interval for the true success proportion will be calculated according to the properties of the binomial distribution.
|
up to 12 cycles
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Overall Survival
Prazo: Up to 3 years from registration
|
Survival time is defined as the time from registration to death due to any cause.
The distribution of survival time will be estimated using the method of Kaplan-Meier.
|
Up to 3 years from registration
|
Progression-free Survival
Prazo: Up to 3 years from registration
|
Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression or death, whichever occurs first.
Progression is defines as having any new lesion or increase by 50% of previously involved sites from nadir.
The distribution of progression-free survival time will be estimated using the method of Kaplan-Meier.
|
Up to 3 years from registration
|
Duration of Response
Prazo: Up to 3 years from registration
|
Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest objective status is first noted to be either a CR or PR to the earliest date progression is documented.
MR for Waldenstrom lymphoma will not be included as a response.
Median duration of response and the confidence interval for the median duration will be computed.
|
Up to 3 years from registration
|
Time to Treatment Failure
Prazo: Up to 3 years from registration
|
Time to treatment failure is defined to be the time from registration to the date at which the patient is removed from treatment due to progression, adverse events, or refusal.
If the patient is considered to be a major treatment violation or is taken off study as a non-protocol failure, the patient will be censored on the date they are removed from treatment.
The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier.
|
Up to 3 years from registration
|
Adverse Events
Prazo: up to 12 cycles (28 days per cycle) of treatment
|
Adverse events were assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 after each cycle of treatment.
The maximum grade for each type of adverse event were recorded for each patient, and frequency tables were reviewed to determine patterns.
For this endpoint, the number of patients receiving a Grade 3, Grade 4, or Grade 5 as their highest reported grade regardless of attribution are reported.
A full list of adverse events are reported in the Adverse Events section of this report.
|
up to 12 cycles (28 days per cycle) of treatment
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Craig Reeder, Mayo Clinic
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Doenças cardiovasculares
- Doenças Vasculares
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Neoplasias
- Distúrbios Linfoproliferativos
- Doenças Linfáticas
- Distúrbios imunoproliferativos
- Linfoma Não-Hodgkin
- Atributos da doença
- Doenças Hematológicas
- Distúrbios hemorrágicos
- Distúrbios hemostáticos
- Paraproteinemias
- Distúrbios das Proteínas Sanguíneas
- Neoplasias de Células Plasmáticas
- Leucemia Linfóide
- Leucemia
- Leucemia de Células B
- Linfoma de Células B
- Linfoma
- Linfoma Folicular
- Recorrência
- Linfoma de Células do Manto
- Linfoma de Células B, Zona Marginal
- Waldenstrom Macroglobulinemia
- Leucemia Linfocítica Crônica de Células B
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Autônomos
- Agentes do Sistema Nervoso Periférico
- Antiinflamatórios
- Agentes Antirreumáticos
- Agentes Antineoplásicos
- Agentes imunossupressores
- Fatores imunológicos
- Antieméticos
- Agentes gastrointestinais
- Glicocorticóides
- Hormônios
- Hormônios, Substitutos Hormonais e Antagonistas Hormonais
- Agentes Antineoplásicos Hormonais
- Agentes Antineoplásicos Alquilantes
- Agentes Alquilantes
- Agonistas Mieloablativos
- Agentes Antineoplásicos Imunológicos
- Dexametasona
- Ciclofosfamida
- Rituximabe
- Bortezomibe
Outros números de identificação do estudo
- MC0883 (Outro identificador: Mayo Clinic)
- P30CA015083 (Concessão/Contrato do NIH dos EUA)
- NCI-2011-02991 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Rituximabe
-
PETHEMA FoundationConcluídoLeucemia linfoblástica aguda | Linfoma de BurkittEspanha
-
Wolfson Medical CenterDesconhecidoLeucemia Linfocítica Crônica Refratária AvançadaIsrael
-
Nantes University HospitalConcluídoLinfoma de Células Grandes DifusoFrança
-
Rennes University HospitalRecrutamentoEsclerose múltipla | Esclerose Múltipla Remitente-RecorrenteFrança
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH); Fogarty...ConcluídoHIV | Linfoma Difuso de Grandes Células BMalauí
-
Paris Cardiovascular Research Center (Inserm U970)Ainda não está recrutandoCardiopatia Reumática em Crianças
-
Centre de Recherches et d'Etude sur la Pathologie...Concluído
-
Hospital Universitario 12 de OctubreInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Fundación... e outros colaboradoresConcluídoNEFROPATIA MEMBRANOSAEspanha
-
First Affiliated Hospital, Sun Yat-Sen UniversitySecond Affiliated Hospital of Guangzhou Medical UniversityDesconhecido
-
Mingzhi ZhangDesconhecidoLinfoma Difuso de Grandes Células BChina